英文简介：

Cardiologyí features high-quality papers from all over the world to keep its readers regularly informed of current strategies in the prevention, diagnosis and treatment of heart disease. These papers not only describe but offer critical appraisals of new developments in non-invasive, invasive, diagnostic and therapeutic methods. The importance of experimental work is also acknowledged through reports covering the function and metabolism of the heart and the morphology and physiology of cardiovascular disease. Special sections in a variety of subspecialty areas reinforce the journalís value as a complete record of recent progress for all cardiologists, internists, cardiac surgeons and clinical physiologists. ''Cardiology'' publishes original reports in research and observations pertaining to cardiovascular physiology, epidemiology, pharmacology, disease and therapy. Only original papers written in English are considered. The articles should be readily comprehensible to a reader who is fluent in English. Therefore, all manuscripts originating from non-English-speaking authors must be edited prior to submission to assure that standard English grammar and usage are observed. This may require help from a colleague or other editorial assistant. It must be evident from the covering letter that this has been done. Submissions that are not edited in this way will not be considered for publication until such editing has been achieved. Manuscripts should be submitted online Online Manuscript Submission Main Sections Original Research Original Research – Clinical Trial Design Submissions will be accepted reporting the study design protocols of planned clinical trials that have been appropriately registered with regulatory authorities. These submissions will be limited to 4500 words and 35 references. Review Turning Basic Research into Clinical Success One or two focused review articles are published in each issue, and should offer an overview of existing concepts and literature in a format assimilable to the largely clinical cardiologist readership, i.e. a readership base with limited sophistication as to methods and terminology associated with cell and molecular biology. Most manuscripts are submitted upon invitation. Authors planning to submit an unsolicited paper are requested to contact the Editorial Office with an outline of the intended contribution. All submissions are subject to peer review. These articles are available also to nonsubscribers in free access on the journal''s website. Submissions should comprise no more than 4,500 words and 50 references. They should have an abstract of approximately 200 words and about 5 key words should be provided. Letter to the Editor Letters to the Editor (max. 1,500 words, including references) are encouraged if they directly concern articles previously published in this journal and issues raised by those articles. The Editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. Novel Insights from Clinical Experience (formerly Case Reports) Contributions to this section are expected to provide novel insight into a clinical problem. Submissions can be based on a single case or a number of similar cases. While a case report can describe an entirely novel clinical condition, we recognise that it is unlikely that most case reports will provide such information. In the more common setting of a description of a well-recognized condition, the most important aspect of the presentation, on which editorial judgments will be based, is the description of the new perspective(s) on the phenotype, pathophysiology, clinical presentation, evaluation strategy and/or management that can be drawn from the case findings. Highlighted boxes containing one or two bullet points on ''Established facts''and ''Novel insights'' are required and should be placed on the first page of the report. These should be selected so as to reinforce the novelty of the clinical observation.

中文简介：（来自Google、百度翻译）

《心脏病学》以来自世界各地的高质量论文为特色，定期向读者介绍当前预防、诊断和治疗心脏病的策略。这些论文不仅描述了非侵入性、侵入性、诊断性和治疗性方法的新发展，而且提供了批判性的评价。通过报道心脏的功能和代谢以及心血管疾病的形态学和生理学，也认识到实验工作的重要性。在各种子专业领域的特殊部分加强了期刊的价值，作为所有心脏病学家、内科医生、心脏外科医生和临床生理学家的最新进展的完整记录。 《心脏病学》发表有关心血管生理学、流行病学、药理学、疾病和治疗的研究和观察的原始报告。 只有英文原版论文才会被考虑。这些文章应该易于英语流利的读者理解。因此，所有来自非英语作者的手稿必须在提交前进行编辑，以确保遵守标准的英语语法和用法。这可能需要同事或其他编辑助理的帮助。从求职信中可以明显看出，这一点已经做到了。没有以这种方式编辑的投稿，在编辑完成之前不会被考虑出版。 稿件应在网上提交 在线提交手稿 主要部分 原始研究 原始研究-临床试验设计 提交的报告将被接受，报告已在监管部门适当注册的计划临床试验的研究设计方案。这些意见书将被限制在4500字和35参考文献。 审查 将基础研究转化为临床成功 每期发表一至两篇重点综述文章，并应以一种主要为临床心脏病学家读者所能接受的格式，对现有的概念和文献进行概述，即读者基础对与细胞和分子生物学相关的方法和术语了解有限。大多数稿件是应邀提交的。计划主动投稿的作者请与编辑部联系，提供投稿提纲。所有参赛作品均须经同行评审。非订阅者也可以免费访问《华尔街日报》网站上的这些文章。提交的论文不应超过4500字和50篇参考文献。他们应该有一个大约200字的摘要和大约5个关键字应该提供。 致编辑的信 给编辑的信(麦克斯)如果直接涉及到本期刊以前发表的文章以及这些文章所提出的问题，则鼓励使用1500字(包括参考文献)。编辑保留在发表前向有关文章的作者提交此类信件副本的权利，以便允许他们在同一期杂志上作出答复。 临床经验的新见解(以前的病例报告) 对这部分的贡献有望为临床问题提供新的见解。提交可以基于单个案例，也可以基于多个类似案例。虽然病例报告可以描述一种全新的临床情况，但我们认识到，大多数病例报告不太可能提供此类信息。设置更为普遍的公认条件的描述,最重要的方面表示,将编辑判断依据,是新视角的描述(s)表型,病理生理学、临床表现,评价策略和/或管理可以从这样的发现。 在报告的第一页，需要用高亮显示的方框，其中包含关于“既定事实”和“新颖见解”的一两个要点。这些应加以选择，以加强临床观察的新颖性。